12:00 AM
Jan 30, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Saridegib: Interim Phase Ib/II data

Infinity stopped an international Phase Ib/II trial after an interim analysis of the double-blind Phase II portion of the trial in 122 patients with previously untreated metastatic pancreatic cancer showed that once-daily oral saridegib plus gemcitabine would not meet the primary endpoint of median OS vs. placebo plus gemcitabine. The company said there was a higher rate of progressive disease in the saridegib plus gemcitabine arm. Specifically, the median OS for saridegib plus gemcitabine was...

Read the full 353 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >